Contact us
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...
The latest podcasts, webinars, interviews and presentations featuring Angiex
31 October 2024
Watch Angiex CEO Dr. Paul Jaminet and founder Dr. Harold Dvorak, a leading authority on angiogenesis, present at a Force Family Office webinar. This engaging session offers an inside look at Angiex’s development of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to target both tumor cells and the blood vessels that feed them
20 September 2024
Join Angiex CEO Dr. Paul Jaminet as he presents at the MedInvest 2024 October Meeting, offering a comprehensive overview of AGX101, the company’s first-in-class TM4SF1-directed antibody-drug conjugate (ADC).
08 September 2024
Angiex's CEO, Paul Jaminet, discusses the company’s innovative approach to cancer therapies, including their focus on TM4SF1-targeted ADCs, and the challenges and opportunities in advancing breakthrough treatments.
04 September 2024
Paul Jaminet, CEO of Angiex, discusses the science behind their TM4SF1-targeted ADC cancer therapies, along with the challenges of bringing novel oncology treatments through clinical development.
21 August 2024
Angiex’s Paul Jaminet and Abzena’s Matthew Stober discuss their partnership on AGX101, a first-in-class TM4SF1-directed ADC in Phase I trials. They explore their collaboration, future plans, and the growing role of ADCs
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...